Abstract: The present invention provides novel antisense oligonucleotide pharmaceutical compositions having higher RNA aggregate-removing activity than conventional pharmaceutical compositions. The pharmaceutical composition of the present invention contains an oligonucleotide having any base sequence of a repeated sequence in which cytosine-adenine-guanine trinucleotides are repeated 5 to 13 times, from the 5? end to the 3? end, and the oligonucleotide has a mixmer structure containing at least two types of RNase H inactive nucleotide analogs. The present invention provides the pharmaceutical composition of the present invention used for the treatment of some symptoms of myotonic dystrophy type 1 disease.

Abstract: A lipocalin-type prostaglandin D2 synthase (L-PGDS) production promoting agent, more specifically an L-PGDS production promoting agent in pericytes or ischemia-induced multipotent stem cells (iSCs) dedifferentiated from pericytes. A substance having an L-PGDS production promoting action is contained in an extract from inflamed tissues inoculated with vaccinia virus. An L-PGDS production promoting agent is highly useful as a prophylactic, therapeutic or relapse prophylactic agent for a disease in which the effect by promotion of L-PGDS expression is expected to be effective, including a cerebrovascular disorder such as cerebral infarction, dementia such as Alzheimer's disease, or a sleep disorder.

Abstract: T cell receptor (TCR) diversity of a subject, including TCR diversity in CD8+ T cell subsets, is used as a predictive indicator of responsiveness of the subject to cancer immunotherapy prior to initiation of the immunotherapy. Exemplified immunotherapy comprises administering an immune checkpoint inhibitor to a subject, wherein a TCR diversity value in CD8+ T cell subsets from the subject, such as CD8+ T cell subpopulations defined by differential cell surface marker expression, is higher than a reference value.

Abstract: Postoperative adhesion formation at an invasion site and migration of neutrophils to the site of surgical invasion are suppressed by administering an anti-IL-6 receptor antibody and/or a neutrophil-neutralizing antibody.

Abstract: Based on the identification of IL-33 as an exacerbating factor in endometriosis and adenomyosis uteri, a therapeutic agent for endometriosis and adenomyosis uteri has an IL-33 antagonist, which is capable of inhibiting the function of IL-33. The IL-33 antagonist is useful for treating, preventing or alleviating endometriosis and uterine adenomyosis uteri.

Abstract: A diseased person distinguishing device includes a temperature pattern calculation unit that calculates a temperature pattern in an exposed region of a subject on the basis of temperature data input from a body surface temperature measurement device that measures the body surface temperature of the subject, and a subject distinguishing unit that applies a learned model that has been learned in advance to the calculated temperature pattern to determine whether the subject is a diseased person or a healthy person.

Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.

Abstract: A swallowing diagnosis apparatus includes a controller which enables a first swallowing determination process of determining whether or not there is an aspiration risk in the swallowing on the basis of respiratory phases before and after a period in which swallowing has been estimated as having occurred; and a second swallowing determination process of extracting reference information including at least one of the sound information and the respiration information in a predetermined period including the period in which swallowing has been estimated as having occurred, obtaining a feature quantity from the extracted reference information, and performing a machine learning process on the obtained feature quantity to determine whether or not there is a possibility of dysphagia in the swallowing; and a display control process of causing a determination result obtained by the first swallowing determination process and a determination result obtained by the second swallowing determination process to be displayed.

Abstract: A lipocalin-type prostaglandin D2 synthase (L-PGDS) production promoting agent, more specifically an L-PGDS production promoting agent in pericytes or ischemia-induced multipotent stem cells (iSCs) dedifferentiated from pericytes. A substance having an L-PGDS production promoting action is contained in an extract from inflamed tissues inoculated with vaccinia virus. An L-PGDS production promoting agent is highly useful as a prophylactic, therapeutic or relapse prophylactic agent for a disease in which the effect by promotion of L-PGDS expression is expected to be effective, including a cerebrovascular disorder such as cerebral infarction, dementia such as Alzheimer's disease, or a sleep disorder.

Abstract: A dysphagia treatment device includes: a current application unit configured to be attached to a target portion of a treated person in order to percutaneously apply current to a biological tissue of the neck including superior laryngeal nerve of the treated person; a control unit configured to control the current application unit such that percutaneous stimulation caused by an interference wave or a pseudo interference wave is applied to the biological tissue of the neck including the superior laryngeal nerve; an operation unit configured to adjust the current to be applied by the current application unit, to a sensory threshold at which the treated person becomes aware of the percutaneous stimulation; and a display unit configured to display index information based on the sensory threshold.

Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.

Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.

Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.

Abstract: A swallowing diagnosis apparatus includes a controller which enables a first swallowing determination process of determining whether or not there is an aspiration risk in the swallowing on the basis of respiratory phases before and after a period in which swallowing has been estimated as having occurred; and a second swallowing determination process of extracting reference information including at least one of the sound information and the respiration information in a predetermined period including the period in which swallowing has been estimated as having occurred, obtaining a feature quantity from the extracted reference information, and performing a machine learning process on the obtained feature quantity to determine whether or not there is a possibility of dysphagia in the swallowing; and a display control process of causing a determination result obtained by the first swallowing determination process and a determination result obtained by the second swallowing determination process to be displayed.

Abstract: This swallowing training apparatus includes: a respiration detection part configured to detect a respiratory motion of a subject; and a controller. The controller is configured to: provide a trigger for swallowing induction to the subject on the basis of a detection result from the respiration detection part; detect that swallowing was performed by the subject; determine whether or not the detected swallowing was at an appropriate timing with respect to the respiratory motion; and output, to outside, information indicating a result of the determination.

Abstract: A dysphagia treatment device includes: a current application unit configured to be attached to a target portion of a treated person in order to percutaneously apply current to a biological tissue of the neck including superior laryngeal nerve of the treated person; a control unit configured to control the current application unit such that percutaneous stimulation caused by an interference wave or a pseudo interference wave is applied to the biological tissue of the neck including the superior laryngeal nerve; an operation unit configured to adjust the current to be applied by the current application unit, to a sensory threshold at which the treated person becomes aware of the percutaneous stimulation; and a display unit configured to display index information based on the sensory threshold.

Abstract: The present invention provides a transgenic non-human mammal retaining, in a specifically expressible state, a DNA encoding IL-33 in the skin, and having one or more features selected from the group consisting of (1) spontaneous onset of dermatitis, (2) increase in the number of inflammatory cells, (3) increase in total IgE concentration, histamine concentration, cytokine concentration and/or chemokine concentration, and (4) increase in scratching time, under SPF (specific pathogen free) breeding conditions, as compared to a corresponding non-transgenic non-human mammal, and the like.

Abstract: A swallowing estimation device includes: a sound detection part configured to detect sound of a larynx portion; a respiration detection part configured to detect respiration; and a swallowing estimation part configured to estimate swallowing based on sound information outputted from the sound detection part and based on respiration information outputted from the respiration detection part. The swallowing estimation part obtains a value of a parameter for swallowing estimation with respect to a biological sound generation interval that corresponds to a respiratory cessation interval longer than or equal to 400 msec, and estimates whether swallowing has occurred in the biological sound generation interval based on whether the obtained value of the parameter satisfies a swallowing determination condition.

Abstract: A swallowing assist device for assisting swallowing includes a respiration detection part, an application unit, and a control part. The respiration detection part detects respiration. The application unit is attached to a target section to apply a stimulus for facilitation of swallowing. The control part controls the application unit. The control part controls the application unit to start application of the stimulus to the target section during an expiration period detected according to a detection signal from the respiration detection part, and terminate the application of the stimulus to the target section during the expiration period.

Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysis and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.